Combined inhibition of DNA methylation and histone acetylation enhances gene re-expression and drug sensitivity in vivo
about
Epigenetic therapy in gastrointestinal cancer: the right combinationSystems biology of cisplatin resistance: past, present and futurePeptidylarginine deiminases in citrullination, gene regulation, health and pathogenesisTreatment of resistant metastatic melanoma using sequential epigenetic therapy (decitabine and panobinostat) combined with chemotherapy (temozolomide).Plant flavone apigenin inhibits HDAC and remodels chromatin to induce growth arrest and apoptosis in human prostate cancer cells: in vitro and in vivo study.Epigenetic therapies for chemoresensitization of epithelial ovarian cancer.The therapeutic potential of class I selective histone deacetylase inhibitors in ovarian cancerOxidative stress and DNA methylation in prostate cancer.Current limitations and future opportunities for epigenetic therapies.Epigenetic therapies as a promising strategy for overcoming chemoresistance in epithelial ovarian cancerMining gene expression signature for the detection of pre-malignant melanocytes and early melanomas with risk for metastasisEpigenetic hierarchy within the MAGEA1 cancer-germline gene: promoter DNA methylation dictates local histone modifications.Transcriptional suppression, DNA methylation, and histone deacetylation of the regulator of G-protein signaling 10 (RGS10) gene in ovarian cancer cells.Epigenetic regulation of cancer-associated genes in ovarian cancer.Therapeutic modulation of epigenetic drivers of drug resistance in ovarian cancer.Decitabine and suberoylanilide hydroxamic acid (SAHA) inhibit growth of ovarian cancer cell lines and xenografts while inducing expression of imprinted tumor suppressor genes, apoptosis, G2/M arrest, and autophagy.Evaluation of azacitidine and entinostat as sensitization agents to cytotoxic chemotherapy in preclinical models of non-small cell lung cancerA phase I and pharmacodynamic study of the histone deacetylase inhibitor belinostat plus azacitidine in advanced myeloid neoplasia.Epigenomics and ovarian carcinoma.New developments in the treatment of peripheral T-cell lymphoma - role of Belinostat.Epigenomics of ovarian cancer and its chemoprevention.Reactivation of epigenetically silenced miR-512 and miR-373 sensitizes lung cancer cells to cisplatin and restricts tumor growth.DNA methylation of hMLH1 correlates with the clinical response to cisplatin after a surgical resection in Non-small cell lung cancerCisplatin resistance: a cellular self-defense mechanism resulting from multiple epigenetic and genetic changes.Epigenetic therapy using belinostat for patients with unresectable hepatocellular carcinoma: a multicenter phase I/II study with biomarker and pharmacokinetic analysis of tumors from patients in the Mayo Phase II Consortium and the Cancer TherapeutiProteasome inhibition rescues clinically significant unstable variants of the mismatch repair protein Msh2.Mismatch repair defects and Lynch syndrome: The role of the basic scientist in the battle against cancerRole of gene methylation in antitumor immune response: implication for tumor progression.Methylation and histone deacetylase inhibition in combination with platinum treatment in patients with advanced malignancies.Minireview: epigenetic changes in ovarian cancer.Cancer-germline antigen vaccines and epigenetic enhancers: future strategies for cancer treatment.TGF-β: friend or foe? The role of TGF-β/SMAD signaling in epigenetic silencing of ovarian cancer and its implication in epigenetic therapy.Current and future directions of clinical trials for ovarian cancer.DNA methylation in cancer development, diagnosis and therapy--multiple opportunities for genotoxic agents to act as methylome disruptors or remediators.Role of epigenomics in ovarian and endometrial cancers.Epigenomics in hematopoietic transplantation: novel treatment strategies.Molecular mechanisms of cisplatin resistance in bladder cancer.Targeting the epigenome in ovarian cancer.Toxicological and metabolic considerations for histone deacetylase inhibitors.Epigenetic profiling joins personalized cancer medicine.
P2860
Q26745709-1385C6E6-7167-489A-801F-008B64985B72Q26863585-586E4CE2-A8A4-485F-92EB-1A1EC45ED7A7Q26991867-23D9429F-2FA0-47A9-B9C3-F9B3ECB737CBQ33416734-E6CDD69F-1B01-4BA3-ABA1-EC7CFF5860F6Q33606387-AAF73009-A873-45DE-A3EA-2D5709C74685Q33621141-95AFD353-27B1-41B2-8DE6-82F734FC1243Q33659166-C1ED3A44-B409-430F-B982-A7A9F0CE312FQ34021985-7279E452-9E57-451E-BBE6-1CC54C8C44D9Q34195077-1BBCA088-2BC8-4612-BC21-F64C4A42E901Q34305438-8980CB5B-7273-4BEB-B8EF-31C45FB6AA0DQ34416127-0C8AFC16-745F-4A7D-BBC7-1AE7EF6920B7Q34615086-A2EB2294-36AF-4288-A999-90823BE92038Q34638065-C4964365-6AF6-4852-9D52-9743B8D413F4Q34874813-A01705B2-30DA-494B-BC4E-713EC12F9DC0Q35076298-4FDE9E1D-C900-4F6D-9C1C-ADD9B052A616Q35109281-1D763EE9-E907-4284-8347-D592C8A62916Q35238397-7E8E3D16-B7A0-4E71-A998-110F779B1B61Q35327711-743D410F-C40D-45DF-A3D9-0D547AAA1587Q35636575-97533F9F-D891-4975-81FF-8B6147FE5DD8Q35703714-ED0CE399-45F5-4C40-B787-76BD74EBDEACQ35711392-BFA139E5-4D2C-4ACC-BF27-80C1B05A313BQ35829861-6D6148DF-FED9-4046-8E37-1F1636EFE9EBQ35854212-74D56CF6-CEEC-4044-A3D8-82BEBC07F444Q36105474-6A7DDE2C-85E1-4859-9C09-AA8B5EBA3142Q36222932-84D1CF80-2245-4E30-9DC2-C64D66E6408FQ36512211-C383DCCE-164B-42E7-AB6F-666A1BCF21C1Q36540568-73B643E9-7D4B-413A-BFA5-CFFAEB4A8FC8Q37132658-4A12C179-45CF-488B-90AA-269BDEA924D2Q37257390-80553885-627C-4158-9807-27425F6CE16CQ37328836-6FC6BCBC-24BD-43E2-A9CE-3EF2CC720FD7Q37737327-22EE4191-9002-49B3-9E03-8EF6961DA4CBQ37798252-BA00A25B-E3EE-4E8C-98CC-A75FCF57EDEAQ37832932-F12E5DE9-9B74-418E-B48E-68D9798632F9Q37873228-4EF73188-EEAF-42E3-889D-5CDF8D9AAC73Q37961734-6A2F48A9-ED07-4E90-B740-73E5020FCAFFQ37962599-08E6604E-A3A6-46A6-9FB9-9E85747D3E18Q37982453-47E9B4BC-6F67-4AF2-9B42-C8A344ADA216Q37984122-D9B0B585-6616-4B18-9E6F-D869FA288A9AQ38071321-CCABDD8B-83AE-430B-A174-5C24D5EB3E1BQ38115623-BF7FF049-AB4E-4660-B6CF-894B5DE58997
P2860
Combined inhibition of DNA methylation and histone acetylation enhances gene re-expression and drug sensitivity in vivo
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on March 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Combined inhibition of DNA met ...... n and drug sensitivity in vivo
@en
Combined inhibition of DNA met ...... and drug sensitivity in vivo.
@nl
type
label
Combined inhibition of DNA met ...... n and drug sensitivity in vivo
@en
Combined inhibition of DNA met ...... and drug sensitivity in vivo.
@nl
prefLabel
Combined inhibition of DNA met ...... n and drug sensitivity in vivo
@en
Combined inhibition of DNA met ...... and drug sensitivity in vivo.
@nl
P2093
P2860
P356
P1476
Combined inhibition of DNA met ...... n and drug sensitivity in vivo
@en
P2093
P2860
P2888
P304
P356
10.1038/SJ.BJC.6604932
P407
P577
2009-03-01T00:00:00Z